🔔Stock Alerts via Telegram — Free for All Users

Stock Comparison

DXCM vs JNJ

Dexcom Inc vs Johnson & Johnson

The Verdict

DXCM takes this one.

Winner
DXCM

Dexcom Inc

7.0

out of 10

Solid Pick
JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$23.8B

Market Cap

N/A
28.4

P/E Ratio

N/A
17.9%

Profit Margin

N/A
32.4%

Return on Equity

N/A
0.5

Debt-to-Equity

N/A
Moderate

Overall Risk

Conservative
7.0

DVR Score

1.0

The Deep Dive

DXCM7.0/10

Dexcom maintains its strong position as a Continuous Glucose Monitoring (CGM) market leader, driven by successful G7 global rollout and promising initial penetration of Stelo into the Type 2 non-insulin market. The company exhibits solid financial health, consistent operational execution (Q4 2025 earnings beat), and positive analyst sentiment with recent upgrades. The absence of previous concerns ...

Full DXCM Analysis
JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.